Central MC3R/MC4R Agonism & Arousal Pathways
Bremelanotide — Melanocortin Receptor Agonist
PT-141, clinically known as bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It is FDA-approved under the brand name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few peptides in this catalog with full regulatory approval and extensive human clinical data.
Unlike phosphodiesterase-5 (PDE5) inhibitors such as sildenafil, which act peripherally on vascular smooth muscle, PT-141 acts centrally through melanocortin receptors in the brain — specifically MC3R and MC4R in the hypothalamus and limbic system. This central mechanism of action represents a fundamentally different approach to sexual dysfunction research.
PT-141 (bremelanotide) has the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, differing from Melanotan II (MT2) by a single modification: the C-terminal amide group of MT2 is replaced by a free carboxylic acid (OH) in PT-141. This modification reduces the compound's melanogenic activity (reducing tanning side effects) while preserving its central melanocortin receptor agonism.
The molecular weight is 1,025.2 Daltons. The cyclic structure, formed by a lactam bridge between aspartate and lysine, confers metabolic stability and enhanced receptor binding affinity.
PT-141 exerts its primary effects through agonism at MC3R and MC4R in the central nervous system, particularly in the hypothalamus, limbic system, and spinal cord. MC4R activation in the medial preoptic area (MPOA) of the hypothalamus — a region critical for sexual motivation and behavior — increases dopaminergic neurotransmission in the mesolimbic pathway, enhancing sexual desire and arousal.
Unlike PDE5 inhibitors, which require sexual stimulation to be effective and act primarily on penile/clitoral blood flow, PT-141 modulates the central neural circuits that generate sexual desire. This distinction is clinically significant: PT-141 can increase sexual motivation in the absence of external stimulation, addressing the desire component of sexual dysfunction rather than the performance component.
PT-141 (Bremelanotide) is a synthetic peptide that works through the brain's melanocortin system to influence sexual arousal. Unlike drugs like Viagra or Cialis, which work by increasing blood flow to genital tissue, PT-141 works centrally — in the brain — activating the neural pathways that generate sexual desire itself. It was FDA-approved in 2019 under the brand name Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141 activates melanocortin receptors (primarily MC3R and MC4R) in the hypothalamus and limbic system — brain regions that regulate motivation, reward, and sexual behavior. This central mechanism produces arousal at the neurological level rather than just the vascular level. In the FDA approval trials, Vyleesi® demonstrated statistically significant improvements in sexual desire and reductions in distress related to low desire compared to placebo.
The distinction between a central (brain-based) and peripheral (blood flow-based) mechanism for sexual function is clinically significant. Many cases of sexual dysfunction, particularly in women, involve desire and arousal at the psychological/neurological level rather than purely vascular issues. PT-141's FDA approval for HSDD validates the melanocortin pathway as a legitimate therapeutic target for sexual health.
PT-141 is FDA-approved as Vyleesi® for female sexual desire disorder, giving it one of the strongest clinical validation profiles in this catalog. Its central mechanism — working through the brain rather than blood vessels — distinguishes it from conventional sexual health drugs. The research-grade peptide supplied by Purgo Labs is for laboratory use only.
MC4R activation in the medial preoptic area (MPOA) increases dopaminergic signaling in the mesolimbic pathway, enhancing sexual desire.
MC3R agonism in limbic structures contributes to arousal and emotional components of sexual motivation.
Central melanocortin activation increases dopamine release in the nucleus accumbens and ventral tegmental area, the reward circuitry of sexual motivation.
MC4R activation in the spinal cord stimulates nitric oxide-mediated pro-erectile signaling, contributing to peripheral arousal responses.
2 cited studies — model, sample size, outcome, and effect size from published literature.
| Study | Model | Sample | Outcome | Effect Size | Level |
|---|---|---|---|---|---|
Diamond LE, et al. (2004) Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic prope… PubMed | Human — Phase II RCT | n=20 | Significant increase in erectile response vs. placebo; centrally mediated | Significant improvement in erectile function scores (p<0.05) | Phase II |
Clayton AH, et al. (2016) Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women PubMed | Human — Phase III RCT (HSDD) | n=1267 | Significant improvement in satisfying sexual events and desire in women with HSDD | SSE increase: +0.7 vs. +0.2 placebo (p<0.001); FDA approved 2019 | Phase III |
Sexual Health Research
≥99% purity · Third-party tested
Use code Health for 15% off
Fast FedEx shipping · 60-day guarantee
| Peptide Class | Cyclic heptapeptide melanocortin agonist |
| Molecular Weight | 1,025.2 Da |
| FDA Approval | Vyleesi® — HSDD in premenopausal women |
| Receptor Targets | MC3R, MC4R (central nervous system) |
| Mechanism Type | Central (hypothalamic) — vs. peripheral PDE5 inhibitors |
| Available Sizes | 10mg vials |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Purgo Labs offers PT-141 with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.
Purchase PT-141 at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.
